(Bloomberg Opinion) — About two months after releasing preliminary Covid-19 vaccine data that sent the stock market into a tizzy, Moderna Therapeutics Inc. finally published a complete look at the initial human trial of its drug late Tuesday — and it promptly moved the market again.Moderna shares surged 20% on the results after the close Tuesday, and stocks in general got a loft as well. Is it warranted? For sure, the expanded results published in the New England Journal of Medicine contain good news about the vaccine’s early attributes. However, they mainly put what the company revealed in its sparse …read more
Source:: Yahoo Finance
